Coherus Oncology
(NASDAQ) CHRS
Coherus Oncology Financials at a Glance
Market Cap
$228.29M
Revenue (TTM)
$46.88M
Net Income (TTM)
-$151.66M
EPS (TTM)
-$1.25
P/E Ratio
-1.19
Dividend
$0.00
Beta (Volatility)
1.66 (High)
Dividend
$0.00
Beta (Volatility)
1.66 (High)
Price
$1.48
Volume
1,288,484.392
Open
$1.42
Price
$1.48
Volume
1,288,484.392
Open
$1.42
Previous Close
$1.48
Daily Range
$1.39 - $1.50
52-Week Range
$0.71 - $2.62
Estimated Earnings Date
Aug 6, 2026
Dividend
$0.00
Beta (Volatility)
1.66 (High)
Price
$1.48
Volume
1,288,484.392
Open
$1.42
Previous Close
$1.48
Daily Range
$1.39 - $1.50
52-Week Range
$0.71 - $2.62
Estimated Earnings Date
Aug 6, 2026
CHRS News
CHRS: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Coherus Oncology
Industry
Biotechnology
Sector
Health CareEmployees
147
CEO
Denny M. Lanfear, MBA
Website
www.coherus.comHeadquarters
Redwood City, CA 94065, US
CHRS Financials
Key Financial Metrics (TTM)
Gross Margin
60%
Operating Margin
-4%
Net Income Margin
-3%
Return on Equity
-861%
Return on Capital
-1%
Return on Assets
-57%
Earnings Yield
-84.03%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$228.29M
Shares Outstanding
154.25M
Volume
1.29M
Avg. Volume
1.15M
Financials (TTM)
Gross Profit
$24.43M
Operating Income
-$179.53M
EBITDA
-$170.20M
Operating Cash Flow
-$138.51M
Capital Expenditure
$0.00
Free Cash Flow
-$138.51M
Cash & ST Invst.
$172.13M
Total Debt
$40.34M
Coherus Oncology Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$12.31M
+62.0%
Gross Profit
$7.62M
+95.3%
Gross Margin
61.86%
N/A
Market Cap
$228.29M
N/A
Market Cap/Employee
$1.00M
N/A
Employees
228
N/A
Net Income
-$37.94M
+32.9%
EBITDA
-$33.87M
+23.4%
Quarterly Fundamentals
Total Cash
$167.05M
+102.7%
Total Debt
$54.37M
-79.9%
Accounts Receivable
$22.51M
-63.9%
Inventory
$4.83M
+37.2%
Long Term Debt
$52.47M
-80.4%
Short Term Debt
$1.90M
+10.2%
Return on Assets
-57.01%
N/A
Return on Invested Capital
-1.27%
N/A
Free Cash Flow
-$57.89M
-124.1%
Operating Cash Flow
-$57.89M
-124.1%